GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.
You may also be interested in...
From Supertankers To Speedboats: Executives Make The Leap From Big Pharma To Start-Ups
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
Q4 Earnings Preview: It's All About Growth Goals And Deal Plans (Part 2)
Industry's big players report fourth quarter results over the next two weeks. Updates on leadership changes, growth targets and deal plans are among the hot topics.
AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.